Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Down 97.2% in May

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 11,793 shares, a decline of 97.2% from the April 30th total of 423,802 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 637,751 shares, the days-to-cover ratio is currently 0.0 days.

Chugai Pharmaceutical Stock Performance

Shares of CHGCY stock traded up $0.02 during trading hours on Friday, reaching $24.74. The company had a trading volume of 77,145 shares, compared to its average volume of 229,951. The stock has a fifty day moving average of $26.33 and a 200-day moving average of $27.37. The company has a market capitalization of $81.43 billion, a price-to-earnings ratio of 27.49 and a beta of 0.63. Chugai Pharmaceutical has a 12-month low of $19.50 and a 12-month high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Friday, April 24th. The company reported $0.22 earnings per share for the quarter. The company had revenue of $2.05 billion during the quarter. Chugai Pharmaceutical had a return on equity of 22.90% and a net margin of 34.98%.

Analyst Ratings Changes

Separately, Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Chugai Pharmaceutical currently has an average rating of “Strong Buy”.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.